RALOX-HAIC在原发性肝癌发病机制中的作用研究进展

doi:10.3969/j.issn.1672-5069.2025.04.040

摘要/Abstract

摘要： 原发性肝癌(PLC)是世界上常见的主要癌症之一,也是恶性肿瘤死亡的第三大常见原因。肝动脉灌注化疗(HAIC)凭借出色的疗效和安全性,在治疗PLC领域获得了越来越多的使用。随着国内学者的积极探索,由奥沙利铂(OXA)和雷替曲塞组成的RALOX-HAIC方案在治疗方面疗效满意。本文就RALOX-HAIC及其联合治疗PLC的应用及前景进行了综述。

关键词: 原发性肝癌, 肝动脉灌注化疗, 奥沙利铂和雷替曲塞方案, 联合治疗

Abstract: Primary liver cancer ( PLC ) is one of the most common cancers in the world and is also the third most common cause of death from malignant tumors. It increases family and social economic burden. In recent years, hepatic artery infusion chemotherapy ( HAIC ) has gained more and more favor in the treatment of patients with PLC due to its excellent efficacy and safety. The raltitrexed and oxaliplatin (RALOX)-HAIC regimen has emerged in this field as the active exploration of domestic scholars get a satisfactory efficacy. In this article, we reviewed the application and prospect of RALOX-HAIC and its combination therapy in dealing with patients with PLC.

Key words: Primary Liver Cancer, Hepatic artery infusion chemotherapy, Raltitrexed/oxaliplatin regimen, Combination therapy

彭乐, 黄古叶, 徐莉虹. RALOX-HAIC在原发性肝癌发病机制中的作用研究进展[J]. 实用肝脏病杂志, 2025, 28(4): 636-640.

Peng Le, Huang Guye, Xu Lihong. Hepatic artery infusion chemotherapy based on oxaliplatin and raltitrexed in treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2025, 28(4): 636-640.

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[2] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol, 2022,77(6):1598-1606.
[3] Singal A G, Kanwal F, Llovet J M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol, 2023,20(12):864-884.
[4] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022,135(5):584-590.
[5] Park J W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int, 2015,35(9):2155-2166.
[6] Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer, 2015,4(3):188-199.
[7] Hohn D C, Stagg R J, Friedman M A, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol, 1989,7(11):1646-1654.
[8] Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. a randomized trial. Ann Intern Med, 1987,107(4):459-465.
[9] Allen-Mersh T G,Earlam S,Fordy C,et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.Lancet, 1994,344(8932):1255-1260.
[10] Toyoda H, Nakano S, Kumada T, et al. Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir. Gan To Kagaku Ryoho, 1993,20(12):1769-1774.
[11] Toyoda H, Nakano S, Kumada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology, 1995,52(4):295-299.
[12] Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther, 2002,1(3):227-235.
[13] Wang Z, Zhou J, Fan J, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs, 2009,18(11):1595-1604.
[14] Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol), 2014,26(8):488-496.
[15] Jackman A L, Taylor G A, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res, 1991,51(20):5579-5586.
[16] Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs, 2016,27(7):689-694.
[17] Cui W, Fan W, Zhang Q, et al. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. Oncotarget, 2017,8(45):79165-79174.
[18] Shao W, Li C, Tang J, et al. Efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer Manag Res, 2019,11:9863-9869.
[19] He J, Sun H, Li F, et al. Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: a multicenter real-world study. Hepatol Res, 2021,51(11):1153-1163.
[20] Bi Y, Wang Y, Zhang W, et al. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. Cancer Imaging, 2023,23(1):19.
[21] Chen S, Yuan B, Yu W, et al. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: a propensity score-matching cohort study. J Surg Oncol, 2022,126(7):1205-1214.
[22] Chen S, Zhang K, Liu W, et al. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: a phase II, single-arm, prospective study. Eur J Cancer, 2020,134:90-98.
[23] Wu Y, Zheng S, Zhang Z, et al. Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed as an alternative option in advanced hepatocellular carcinoma patients with failure of, or unsuitability for, transarterial chemoembolization. Medicina (Kaunas), 2022,58(10):824-828.
[24] Chen S, Yu W, Zhang K, et al. Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis. Gastroenterol Rep (Oxf), 2022,10:goac16.
[25] Kraj L, Chmiel P, Gryziak M, et al. Impact of thrombocytopenia on survival in patients with hepatocellular carcinoma: updated meta-analysis and systematic review. Cancers (Basel), 2024,16(7):432-435.
[26] Leung J H, Wang S Y, Leung H, et al. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis. Front Oncol, 2024,14:1344798.
[27] Tan Z, Zhang J, Xu L, et al. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One, 2023,18(10):e290644.
[28] 徐永康, 付舒敏, 李丹, 等. 肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展. 介入放射学杂志, 2023,32(01):94-97.
[29] National Health Commission Of The. 原发性肝癌诊疗指南(2024年版). 临床肝胆病杂志, 2024,40(05):893-918.
[30] Ge N, Wang H, He C, et al. Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?. J Interv Med, 2023,6(2):59-63.
[31] Liu B, Gao S, Guo J, et al. Efficacy and safety of hepasphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular carcinoma. J Hepatocell Carcinoma, 2024,11:477-488.
[32] Zhu L Z, Xu S, Qian H L. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World J Gastroenterol, 2018,24(23):2501-2507.
[33] Liu B, Zhu X, Gao S, et al. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. J Interv Med, 2019,2(2):91-96.
[34] Tu X, Zhang W, Li S, et al. Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens. Eur J Med Res, 2024,29(1):465.
[35] Cai M, Liang L, Zhang J, et al. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Int J Surg, 2024.
[36] Mei J, Li S H, Li Q J, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma, 2021,8:167-176.
[37] Zhou S A, Zhou Q M, Wu L, et al. Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: a network meta-analysis. World J Gastrointest Oncol, 2024,16(8):3672-3686.
[38] Li Z, Xu Y, Qu W, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Oncol Lett, 2023,26(6):534.
[39] Chen S, Shi F, Wu Z, et al. Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study. J Hepatocell Carcinoma, 2023,10:1209-1222.
[40] Wang W, Li R, Li H, et al. Addition of immune checkpoint inhibitor showed better efficacy for infiltrative hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy and lenvatinib: a multicenter retrospective study. Immunotargets Ther, 2024,13:399-412.
[41] Zang M, Hu X, Yuan G, et al. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: a retrospective study. Int Immunopharmacol, 2023,125(Pt A):111019.
[42] Luo L, Xiao Y, Zhu G, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol, 2022,12:1004652.
[43] 李榕, 李文利, 胡晓云, 等. RALOX-HAIC联合免疫检查点抑制剂及靶向药物治疗中晚期肝癌的疗效分析. 中国肿瘤临床, 2023,50(11):555-560.
[44] Xiao Y, Deng W, Luo L, et al. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma. BMC Cancer, 2024,24(1):588.
[45] Xiao Y, Zhu G, Xie J, et al. Pretreatment neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and camrelizumab. J Hepatocell Carcinoma, 2023,10:2049-2058.